Profile of Serum Heat Shock Protein-27 Level in Patients with Salivary Gland Tumor

Negar Moghadasi 1, DMD; Azadeh Andisheh-Tadbir 2, DMD, MSd; Amin Samiee 3, DMD; Shima Torabi Ardekani 4, DMD, MSd; Bijan Khademi 5, DMD, MSd; Mahyar Malekzadeh 5, PhD; Razieh Zare 6, DMD, MSd;

1 Undergraduate Student, School of Dentistry, International Branch, Shiraz University of Medical Sciences, Shiraz, Iran.
2 Oral and Dental Disease Research Center, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
3 Postgraduate, Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
4 Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran.
5 Dept. of Otorhinolaryngology, Khalili Hospital, Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.
6 Shiraz Institute for Cancer Research, Shiraz University of Medical Sciences, Shiraz, Iran.

KEY WORDS
Adenoid cystic carcinoma;
Salivary gland tumor;
Mucoepidermoid carcinoma;
HSP27;
Pleomorphic adenoma;

ABSTRACT

Statement of the Problem: Heat shock protein 27 (HSP27) plays important roles in many cellular processes and has been implicated in different types of diseases such as cancers.

Purpose: This study aimed to evaluate the serum level of HSP27 in patients with salivary gland tumors and to determine its possible correlation with the prognosis of the disease.

Materials and Method: This cross-sectional study was performed on 60 patients with salivary gland tumor including 16 pleomorphic adenoma, 33 adenoid cystic carcinoma, 6 mucoepidermoid carcinoma, 5 acinic cell carcinoma, and 28 healthy control subjects. The control cases were healthy blood donors who matched the study group in age and sex. Serum samples were obtained from the clotted blood and HSP27-concentrations were measured with sandwich enzyme-linked immunosorbent assay (ELISA). Statistical analysis was performed by using one-way ANOVA, post Hoc test, independent sample t-test, and ROC analysis. A p value of less than 0.05 was considered as significant.

Results: The mean serum level of HSP27 was 3956.1±3830.1 (pg/ml) in patients with malignant salivary gland tumor, which was significantly higher than that in benign salivary gland tumor (752.2±485.6) and healthy controls (602.3±575.8) (p<0.001). However, there was no significant difference in the HSP27 serum levels between the patients with benign salivary gland tumors and healthy controls (p=0.2). No association was detected between the mean serum levels of HSP27 and clinicopathologic factors such as age, sex, stage and nodal metastasis (p>0.05), except for the tumor size (p=0.04).

Conclusion: The HSP27 concentration increased in patients with malignant salivary gland tumors. Moreover, the HSP27 level was correlated with tumor growth, invasiveness, and diagnosability. Yet, larger clinical studies are required to explore its prognostic value.

Corresponding Author: Zare R. Dept. of Oral and Maxillofacial Pathology, School of Dentistry, Shiraz University of Medical Sciences, Shiraz, Iran. Tel: +98-71-36263193-4 Fax: +98-71-36270325 Email: zare.r.sums.1394@gmail.com

Introduction
Salivary gland tumors comprise 1-4% of human neoplasms [1]. Pleomorphic adenoma (PA), the most common benign salivary gland tumor, has an incidence of 70% [2]. Mucoepidermoid carcinoma (MEC) and adenoid cystic carcinoma (ACC) [3] are the most common salivary gland cancers that can metastasize to the regional lymphatics or distant organs. It has been shown that salivary gland tumors have numerous complexities in the site of occurrence, structural origins, histopathologic features, clinical appearance and prognosis [4-5]. Therefore, their mechanism of development and prognosis is...
significantly different [6]. Moreover, the salivary gland tumors have recurrence potential after treatment; thus, finding methods of early diagnosis and prevention of these tumors is very important in clinical cancers [6]. Heat shock proteins (HSPs) are a kind of important molecular chaperones expressed in the nuclei, cytoplasm, and cell membrane of both eukaryotic and prokaryotic organisms, which induce cell growth regulation and proliferation [7-8]. HSPs family is subdivided into four major families according to their activity [7-9]. HSPs, plays important roles in many cellular processes such as cell differentiation [8], inhibition of apoptosis [10], thermotolerance, cytoskeleton dynamics, and signal transduction [11]. HSPs has also been implicated in different types of diseases including cancers [12], renal injury and fibrosis [13], as well as cardiovascular and neurodegenerative diseases [14]. Over-expression of HSPs has been found in different tumor types and is involved in tumor formation and development, prognosis, treatment and biological behaviors [15-16]. Therefore, it can be a therapeutic target and potential biomarker for diagnosis and prognosis [12]. In a recent study by Vahen-Kepenekian et al. [17], it was demonstrated that HSPs overexpression in the cytosol of malignant transformed cells resulted in their translocation into the extracellular serum. The overexpression of HSPs in the serum might also be the result of its release following the stress-induced death of the necrotic cells [17].

Guilan et al. [6] showed the overexpression of HSPs in the cytoplasm of the tumoral epithelium in the salivary gland tissue and found a negative correlation between HSPs tissue level and the tumor size, invasion, and metastasis. Accordingly, this study was conducted to evaluate the serum level of HSPs in patients with salivary gland tumors and to determine if it has a correlation with prognosis or not. It seems that HSPs can be a novel target for increasing the effect of cancer treatment; therefore, this study was designed to assess and compare the serum level of HSPs in the most common benign and malignant salivary gland tumors and to consider whether its serum level was correlated with any tumor characteristics such as tumor grade and stage.

**Materials and Method**

A total of 60 patients with salivary gland tumor (16 PA, 33 ACC, 6 MEC and 5 acinic cell carcinoma) and 28 healthy control subjects were engaged in this study. All the study patients were associated by ENT Department of the School of Medicine of Shiraz University of Medical Sciences. All the samples diagnosis were salivary gland tumor. The control cases were healthy blood donors who were matched with the study group based on their age and sex. The Ethics committee of Shiraz University of Medical Sciences approved this study and all the participants were informed about the nature of the study and agreed to participate by signing an informed consent form. Serum samples were obtained from clotted blood following centrifugation at 4°C and stored at 80°C until the time of analysis. HSPs concentrations were measured with sandwich enzyme-linked immunosorbent assay (ELISA) following the manufacturer’s instructions (BMS; GmbH, Germany).

Statistical analysis was performed by using one-way ANOVA, post hoc test, independent sample t-test, and ROC analysis. A p value of less than 0.05 was considered as significant.

**Results**

Table 1 shows the clinical characteristics of 44 patients with malignant salivary glands. The mean age of patients with malignant salivary gland tumor was 51.4±17.2 years old (ranging 21-80). The mean age of patients with benign tumors was 45.6±14.6 years old (ranging 22-71) and healthy controls were 49.7±17.2 years old (ranging 19-85). The mean serum level of HSPs was 3956.1±3830.1 (pg/ml) in patients with malignant salivary gland tumor, which was significantly higher than that in those with benign salivary gland tumor (752.2±485.6) and healthy controls (602.3±575.8) (p<0.001). The serum levels of HSPs in patients with benign salivary gland tumors and control groups had not significant differences (p=0.2) (Table 2). The ROC curve analysis showed that the optimal cut-off value for HSPs was 809.01(pg/ml), indicating that HSPs serves as a diagnostic marker for malignant salivary gland tumors. This yielded a sensitivity of 75% and specificity of 75%.

| Table 1: The base line data of all groups |
|-----------------------------------------|
| **Patients** | **Number** | **Age (Mean (range))** |
| Benign tumors | 16 | 45.6±14.6 (22-71) |
| Malignant tumors | 44 | 51.4±17.2 (21-80) |
| Control | 28 | 49.7±17.2 (20-85) |
| Total | 60 | 48.3±16.2 (20-78) |
There was no correlation between the mean serum levels of HSP27 and clinicopathologic factors such as age, sex, stage and nodal metastasis ($p > 0.05$), except for the tumor size ($p = 0.04$). The serum level of HSP27 was significantly higher in patients with larger tumor size than the small tumor size.

**Discussion**

Biomarkers are used to detect and monitor the growth of the tumor and evaluate the effect of anti-cancer therapies [18]. A major disadvantage of tissue-based biomarkers is their limited accessibility and the risk of developing infection due to invasive surgery. Therefore, blood-derived biomarkers are better than biopsies in detecting and monitoring the tumor in that these samples can be taken before, during and after treatment with minimal invasion [19].

HSPs are a series of highly conserved proteins that play a crucial role in maintaining protein homeostasis [20]. HSPs are produced under stressful conditions and they participate in folding and assembling the proteins [12]. However, HSPs can be secreted in the blood circulation and have been shown to interact with some immune cells [21]. It has been demonstrated that HSP27 expression is crucial for tumor development and is involved in tumor behavior and prognosis [22-23]. Increased HSP27 expression has been reported in different cancers [24-25] and is associated with poor prognosis in the liver, prostate, and gastric carcinoma [26-27].

In the present study, circulation of HSP27 level was obviously upregulated in patients with malignant Salivary gland tumors than in those with benign tumors and healthy control subjects. This was in line with those of the previous studies that evaluated the HSP27 level in breast cancer, non-small cell lung cancer, pancreatic and gastric adenocarcinoma [28-31]. This study demonstrated that HSP27 level can be used as a discriminating biomarker for differentiating patients with and without cancer. This was consistent with the results of Lia et al. [27] and De et al. [32-33]. Lia et al. [27] stated that Heat shock protein 27 levels were significantly higher in cancer and pancreatitis compared with control ($p < 0.001$ for both) and De et al. [32-33] reported that the use of HSP 27 ELISA could be extremely useful in evaluating the role of soluble HSP 27 in breast or other cancers.

Cell damage or necrotic cell death can cause the release of intracellular HSP into circulation that could lead to elevated HSP serum concentration [34]. In this study, HSP elevation in patients with malignant salivary gland tumor might be related to its increased production and release because of cell damage. In salivary gland carcinoma, HSP27 level did not correlate with prognostic factors, except for the tumor size. In a recent study on non-small cell lung cancer, it was found that the serum level of HSP27 was significantly elevated in patients at the advanced stage than the early stages [35]. However, no significant relationship was found between the serum level of HSP27 and histological types and sex [35].

Van Eden et al. [36] showed that HSP released by the cells were biologically active molecule, confirming the hypothesis that elevated circulating HSP27 level in the serum can lead to tumor growth and invasiveness.

Different mechanisms have been proposed to explore the role of HSP27 in tumor progression. Furthermore, it has been shown that HSP27 has the ability to block apoptotic cell death and may contribute to tumor growth via inhibition of apoptosis [37]. It can also directly interact with other pro-survival proteins and regulate the cell survival [38].

In a recent study by Banerjee et al. [30], it was reported that increased HSP27 levels in human breast tumor could induce unresponsiveness in T cells. Moreover, HSP induced significant neovascularization via macrophage differentiation, and was critically important for tumor growth [30]. They suggested that immune suppression induced by HSP27 was a new tumor growth supporting mechanism that might lead to novel treatment strategies by targeting the released HSP27 [30]. Furthermore, our results showed the positive association of HSP27 serum levels with tumor size; this finding suggests that

| Table 2: Clinicopathologic features and the mean HSP27 level of the patients with malignant salivary gland tumor |
|---------------|-----------------|-----------------|-----------------|-----------------|
|               | Number (%)      | Mean HSP27 (pg/ml) | $p$ Value |
| **Tumor Size**|                 |                  |       |
| T1+T2         | 32(26.7)        | 3011.6±3426.5    | 0.04   |
| T3+T4         | 12(26.7)        | 6477.1±6268.5    |       |
| **Lymph node involvement** |  |                  |       |
| N0            | 28(63.6)        | 3701.1±4111.7    | 0.5    |
| N1            | 16(36.4)        | 4402.4±3359.9    |       |
| **Distant Metastasis** |  |                  |       |
| M0            | 41(93.1)        | 3742.6±3549.9    | 0.08   |
| M1            | 3(6.9)          | 6874.1±7046.9    |       |
| **Stage**     |                 |                  |       |
| I+ II         | 20(45.5)        | 3117.7±3495.05   | 0.3    |
| III+ IV       | 24(54.5)        | 4654.8±4026.8    |       |
the serum level of HSP27 is related to disease condition in salivary gland tumors. It might be suggested that the mechanism of HSP27 through angiogenesis may lead to the growth of the tumor. Hsu et al. [11] demonstrated that HSP27 overexpression was associated with resistance to chemotherapy. Resistance to chemotherapy and radiotherapy has been reported in malignant salivary gland tumor [39]. Resistance to chemotherapy, in salivary gland cancer may partly contribute to elevated HSP27.

This study could not evaluate the expression of HSP27 and the relationship between HSP27 expression and its serum level. Therefore, further studies are required to explore this relationship.

Conclusion
This study showed that HSP27 concentration increased in patients with malignant salivary gland tumors and besides its diagnostic ability, its level was correlated with tumor growth and invasiveness. Nevertheless, larger clinical studies are required to verify its prognostic value.

Acknowledgment
The authors thank the Vice-Chancellery of Shiraz University of Medical Sciences for supporting this research (Grant #92-01-03-6495). This manuscript was based on the thesis by Negar Moghadasi for partial fulfillment of DDS degree. The authors thank Dr. M. Vossoughi of the Dental Research Development Center of the Dental School, for the statistical analysis.

Conflict of Interest
The authors declare that they have no conflict of interest.

References
[1] Gruden G, Carucci P, Lolli V, Cosso L, Dellavalle E, Rolle E, et al. Serum heat shock protein 27 levels in patients with hepatocellular carcinoma. Cell Stress Chaperones. 2013; 18: 235-241.
[2] Feng JT, Liu YK, Song HY, Dai Z, Qin LX, Almofti MR, et al. Heat-shock protein 27: a potential biomarker for hepatocellular carcinoma identified by serum proteome analysis. Proteomics. 2005; 5: 4581-4588.
[3] Banerjee S, Lin CF, Skinner KA, Schifflauer LM, Peacock J, Hicks DG, et al. Heat shock protein 27 differentiates tolerogenic macrophages that may support human breast cancer progression. Cancer Res. 2011; 71: 318-327.
[4] Kepenekian V, Aloy MT, Magne N, Passot G, Armanda E, Decullier E, et al. Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis. Cell Stress Chaperones. 2013; 18: 623-630.
[5] Wang G, Gu X, Chen L, Wang Y, Cao B, E Q. Comparison of the expression of 5 heat shock proteins in benign and malignant salivary gland tumor tissues. Oncol Lett. 2013; 5: 1363-1369.
[6] Baumhoer D, Tornillo L, Stadlmann S, Roncalli M, Diamantis EK, Terracciano LM. Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples. Am J Clin Pathol. 2008; 129: 899-906.
[7] Khalil AA, Kabapy NF, Deraz SF, Smith C. Heat shock proteins in oncology: diagnostic biomarkers or therapeutic targets? Biochim Biophys Acta. 2011; 1816: 89-104.
[8] Scroggins BT, Robzyk K, Wang D, Marcu MG, Tsutsui M, Beeke K, et al. An acetylation site in the middle domain of Hsp90 regulates chaperone function. Molecular cell. 2007; 25: 151-159.
[9] Jiang Y, Wang X, Guo Y, Li W, Yang S, Li W, et al. Expression of Heat Shock Protein 27 in Benign Prostatic Hyperplasia with Chronic Inflammation. Med Sci Monit. 2015; 21: 2976-2985.
[10] Korneeva I, Bongiovanni AM, Girotra M, Caputo TA, Witkin SS. Serum antibodies to the 27-kd heat shock protein in women with gynecologic cancers. Am J Obstet Gynecol MFM. 2000; 183: 18-21.
[11] Wang F, Jing X, Wang T, Li G, Li T, Zhang Q, et al. Differential diagnostic value of GPC3-CD34 combined staining in small liver nodules with diameter less than 3 cm. Am J Clin Pathol 2012; 137: 937-945.
[12] Saikali Z, Sinnett D. Expression of glypican 3 (GPC3) in embryonal tumors. Int J Cancer. 2000; 89: 418-422.
[13] Vidyasagar A, Reese S, Acun Z, Hulett D, Djimali A. HSP27 is involved in the pathogenesis of kidney tubulointerstitial fibrosis. Am J Physiol Renal Physiol. 2008; 295: F707-F716.
[14] Ghayour-Mobarhan M, Saber H, Ferns GA. The potential role of heat shock protein 27 in cardiovascular disease. Clinica chimica acta. Clin Chim Acta. 2012; 413: 15-24.
[15] Guo QY, Yuan M, Peng J, Cui XM, Song G, Sui X, et al. Antitumor activity of mixed heat shock protein/peptide vaccine and cyclophosphamide plus interleukin-12 in mice sarcoma. J Exp Clin Cancer Res CR. 2011; 30: 24.
[16] Park SJ, Kostic M, Dyson HJ. Dynamic Interaction of Hsp90 with Its Client Protein p53. J Mol Biol. 2011; 411: 158-173.

[17] Grozdanov PN, Yovchev MI, Dabeva MD. The oncofetal protein glypican-3 is a novel marker of hepatic progenitor/oval cells. Lab Invest. 2006; 86: 1272-1284.

[18] Madu CO, Lu Y. Novel diagnostic biomarkers for prostate cancer. J Cancer. 2010; 1: 150-177.

[19] Gehrmann M, Cervello M, Montalto G, Cappello F, Gulino A, Knape C, et al. Heat shock protein 70 serum levels differ significantly in patients with chronic hepatitis, liver cirrhosis, and hepatocellular carcinoma. Front Immunol. 2014; 5: 307.

[20] Beere HM. "The stress of dying": the role of heat shock proteins in the regulation of apoptosis. J Cell Sci. 2004; 117: 2641-2651.

[21] van Eden W, van der Zee R, Prakken B. Heat-shock proteins induce T-cell regulation of chronic inflammation. Nat Rev Immunol. 2005; 5: 318-330.

[22] Ciocca DR, Calderwood SK. Heat shock proteins in cancer: diagnostic, prognostic, predictive, and treatment implications. Cell Stress Chaperones. 2005; 10: 86-103.

[23] Calderwood SK, Khaleque MA, Sawyer DB, Ciocca DR. Heat shock proteins in cancer: chaperones of tumorigenesis. Trends Biochem Sci. 2006; 31: 164-172.

[24] Arrigo AP, Simon S, Gibert B, Kretz-Remy C, Nivon M, Czekalla A, et al. Hsp27 (HspB1) and alphaB-crystallin (HspB5) as therapeutic targets. FEBS Lett. 2007; 581: 3665-3674.

[25] Shirakawa H, Suzuki H, Shimomura M, Kojima M, Gotohda N, Takahashi S, et al. Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma. Cancer science. 2009; 100: 1403-1407.

[26] Foda AARM, Mohammad MA, Abdel-Aziz A, El-Hawary AK. Relation of glypican-3 and E-cadherin expressions to clinicopathological features and prognosis of mucinous and non-mucinous colorectal adenocarcinoma. Tumor Biology. 2015; 36: 4671-4679.

[27] Romani AA, Crafa P, Desenazioni S, Graiani G, Lagrasta C, Sianesi M, et al. The expression of HSP27 is associated with poor clinical outcome in intrahepatic cholangiocarcinoma. BMC Cancer. 2007; 7: 232.

[28] Howe HL, Wingo PA, Thun MJ, Ries LA, Rosenberg HM, Feigal EG, et al. Annual report to the nation on the status of cancer (1973 through 1998), featuring cancers with recent increasing trends. J Natl Cancer Inst. 2001; 93: 824-842.

[29] Melle C, Ernst G, Escher N, Hartmann D, Schimmel B, Bleul A, et al. Protein profiling of microdissected pancreatic carcinoma and identification of HSP27 as a potential serum marker. Clin Chem. 2007; 53: 629-635.

[30] De Cat B, Muyldermans SY, Coomans C, Degeest G, Vanderschueren B, Creemers J, et al. Processing by pro-protein convertases is required for glypicanc-3 modulation of cell survival, Wnt signaling, and gastrulation movements. J Cell Biol. 2003; 163: 625-635.

[31] Zimmermann M, Nickl S, Lambers C, Hacker S, Mitterbauer A, Hoetzenecker K, et al. Discrimination of clinical stages in non-small cell lung cancer patients by serum HSP27 and HSP70: a multi-institutional case-control study. Clinica chimica acta; Clin Chim Acta. 2012; 413: 1115-1120.

[32] De AK, Roach SE. Detection of the soluble heat shock protein 27 (hsp27) in human serum by an ELISA. J Immunol assay Immunoch. 2004; 25: 159-170.

[33] Liao WC, Wu MS, Wang HP, Tien YW, Lin JT. Serum heat shock protein 27 is increased in chronic pancreatitis and pancreatic carcinoma. Pancreas. 2009; 38: 422-426.

[34] Srivastava P. Interaction of heat shock proteins with peptides and antigen presenting cells: chaperoning of the innate and adaptive immune responses. Annu Rev Immunol. 2002; 20: 395-425.

[35] Seethala RR. An update on grading of salivary gland carcinomas. Head Neck Pathol. 2009; 3: 69-77.

[36] Peters M, Farias E, Colombo L, Filmus J, Puricelli L, de Kier Joffe EB. Inhibition of invasion and metastasis by glypican-3 in a syngeneic breast cancer model. Breast Cancer Res Treat. 2003; 80: 221-32.

[37] Arnal ME, Lalles JP. Gut epithelial inducible heatshock proteins and their modulation by diet and the microbiota. Nutr Rev. 2016; 74: 181-197.

[38] Zhao M, Ding JX, Zeng K, Zhao J, Shen F, Yin YX, et al. Heat shock protein 27: a potential biomarker of peritoneal metastasis in epithelial ovarian cancer? Tumour biology: Tumour Biol. 2014; 35: 1051-1056.

[39] Ota T, Ota K, Jono H, Fujimori H, Ueda M, Shinriki S, et al. Midkine expression in malignant salivary gland tumors and its role in tumor angiogenesis. Oral Oncol. 2010; 46: 657-661.